CentralCharts: Supercharge your portfolio with groundbreaking tools.

Join Ian King as Europe's biggest company Novo Nordisk raises its forecasts fuelled by high demand for its weight loss and ......

...

Printing the future: The world's largest 3D Printer is developing houses with eco-friendly, recyclable materials. Subscribe: ......

Apex Fundrock Limited (MISL) Form 8.3 - Apex Fundrock Limited : Re Tyman plc 02-May-2024 / 11:54 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Chelverton Asset Management (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies...

QUANTA SERVICES REPORTS FIRST QUARTER 2024 RESULTS PR Newswire HOUSTON, May 2, 2024 First Quarter Consolidated Revenues of $5.03 Billion * First Quarter GAAP Diluted EPS of $0.79 and Adjusted Diluted EPS of $1.41* Net Income Attributable to Common Stock of $118.4 Million and Adjusted EBITDA of $387.3 Million * Cash Flow From Operations of $238.0 Million * and Free Cash Flow of $181.2 Million* Remaining Performance Obligations of $14.9 Billion * and Total Backlog of $29.9 Billion * Raising...

AMETEK Announces Record First Quarter Results and Raises 2024 Guidance PR Newswire BERWYN, Pa., May 2, 2024 BERWYN, Pa. , May 2, 2024 /PRNewswire/ -- AMETEK, Inc. (NYSE: AME) today announced its financial results for the first quarter ended March 31, 2024 . AMETEK's first quarter 2024 sales were a record $1.74 billion , a 9% increase over the first quarter of 2023. On a GAAP basis, first quarter earnings per diluted share were $1.34 . Adjusted earnings in the quarter were $1.64 per diluted...

The OECD has released its latest economic outlook and said it expects steady global growth in 2024 and 2025. READ MORE ......

KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase 1 in the second half of 2024 and KT-294 (TYK2) expected to start Phase 1 in the first half of 2025, both with Phase 1 data in 2025 KT-253 (MDM2) and KT-333 (STAT3) Phase 1 dose escalation studies ongoing with clinical data updates at ASCO and EHA, respectively Well-capitalized with $745 million in cash as of March 31, 2024, and runway into the...